Natera (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 41,124 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $185,956.32.
• On Monday, April 27th, Steven Leonard Chapman sold 5,838 shares of Natera stock. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32.
• On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The stock was sold at an average price of $204.13, for a total value of $1,147,822.99.

Natera Trading Down 3.1%

Shares of NASDAQ:NTRA opened at $215.31 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The business has a fifty day simple moving average of $204.19 and a 200 day simple moving average of $216.06. The firm has a market cap of $30.83 billion, a price-to-earnings ratio of -132.09 and a beta of 1.56.

Analysts Set New Price Targets

Several analysts recently issued reports on NTRA shares. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. The Goldman Sachs Group initiated coverage on Natera in a report on Friday. They set a “neutral” rating and a $245.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Morgan Stanley cut their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Finally, BTIG Research cut their target price on Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $256.12.

Hedge Funds Weigh In On Natera

Institutional investors have recently made changes to their positions in the business. Reflection Asset Management bought a new position in shares of Natera in the fourth quarter worth about $29,000. Palladiem LLC bought a new position in shares of Natera in the fourth quarter worth about $31,000. Horizon Investments LLC bought a new position in shares of Natera in the third quarter worth about $32,000. International Assets Investment Management LLC increased its stake in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares during the period. Finally, Bank of Jackson Hole Trust increased its stake in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the period. 99.90% of the stock is currently owned by institutional investors.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.